ProteoTech, Inc.
12040 115th Ave., NE
Kirkland, WA 98034

 

Office: (425) 823-0400
Fax: (425) 823-8508
E-mail: info@proteotech.com

 

Close Window

A World Leader in Therapeutics and

Diagnostics Targeting Amyloid Diseases

 

ProteoTech's intellectual property estate covering new proprietary technologies currently consists of over 173 patents in its portfolio, including 88 issued patents in the US and Internationally. This extensive portfolio covers technologies relating to:

 

  • Alzheimer's disease
  • Parkinson's disease
  • Other amyloid diseases such as Systemic AA Amyloidosis, and Type 2 Diabetes

 

This extensive landscape of intellectual property covers a wide range of applications including:

 

  • Therapeutics (compositions of matter, new chemical entities, synthetic routes and methods of use)
  • Diagnostics for Alzheimer's and Parkinson's disease
  • Platform in vitro and animal model screening technologies for the development of new compounds
News

April, 2009 ProteoTech presents at the 11th annual C21 BioVentures Conference in Napa, California

April, 2009 ProteoTech meets all scientific milestones for the Michael J. Fox foundation LEAPS award to continue development of Synuclere for treatment of Parkinson's disease.

March 09, 2009 ProteoTech presents at 9th International Conference for Alzheimer's and Parkinson's Disease – Prague, Czech Republic, March 11-15, 2009

February 26, 2009 ProteoTech receives funding from The Michael J. Fox Foundation for Parkinson's Disease research to develop tools for imaging Alpha-Synuclein aggregation in living Parkinson's Brain

December, 2008 ProteoTech's Alzheimer's Drug Exebryl-1® was featured in the Dec 2008 Issue of Reader's Digest

November 11, 2008 ProteoTech presents at Rodman & Renshaw's 10th Annual Healthcare Conference

August 07, 2008 ProteoTech's Exebryl-1® enters human clinical trials for the treatment of Alzheimer's Disease

July 29, 2008 Exebryl-1® Phase I human clinical trial for Alzheimer's disease commences

July 25, 2008 ProteoTech presents at International Alzheimer's Conference—Chicago, IL.

May 28, 2008 ProteoTech receives clearance from FDA to proceed with Phase I human clinical trials for Exebryl-1®

May 15, 2008 ProteoTech receives NIH SBIR Phase II continuation award for systemic amyloidosis therapeutic research

April 28, 2008 ProteoTech files IND for Exebryl-1® for the treatment of mild-to-moderate Alzheimer's Disease